Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes

Ruxolitinib is an FDA-approved treatment of intermediate- and high-risk myelofibrosis. In the phase 3 COMFORT studies, ruxolitinib reduced spleen volume in patients with myelofibrosis, with a median time to response of 3 months. However, nearly 20% of patients discontinued by month 4 with few treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerds, Aaron T., Yu, Jingbo, Scherber, Robyn M., Paranagama, Dilan, Kish, Jonathan K., Visaria, Jay, Singhal, Mukul, Verstovsek, Srdan, Pemmaraju, Naveen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393808/
https://www.ncbi.nlm.nih.gov/pubmed/35008087
http://dx.doi.org/10.1159/000520440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393808/
https://www.ncbi.nlm.nih.gov/pubmed/35008087
http://dx.doi.org/10.1159/000520440

Ejemplares similares